0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
This Month in Archives of Neurology |

This Month in Archives of Neurology FREE

Arch Neurol. 2009;66(2):151-152. doi:10.1001/archneurol.2008.572.
Text Size: A A A
Published online

BLOOD PROTEIN SIGNATURE FOR EARLY ALZHEIMER DISEASE

Britschgi and Wyss-CorayArticle describe a blood-based panel of secreted signaling proteins that distinguishes between blinded samples from patients with Alzheimer disease and those of control subjects with high accuracy. A clinically useful and reliable biomarker blood test is now able to be implemented on a broad basis to diagnose the disease in its earliest phase.

EXTRANIGRAL PARKINSON DISEASE

Lim and colleaguesArticle address selected clinical, anatomical, pathological, and biochemical correlates of the early premotor symptoms of Parkinson disease, later nonmotor fluctuations, and advanced dopa-unresponsive motor and nonmotor features. The recognition of early features that predate classic motor symptoms will be important as effective neuroprotective therapy becomes available.

CONTRIBUTION OF WHITE MATTER LESIONS TO GRAY MATTER ATROPHY IN MULTIPLE SCLEROSIS

Sepulcre et alArticle in an elegant study, show that focal white matter damage is associated with upstream gray matter atrophy, suggesting that retrograde damage of the pericaria from axonal injury in multiple sclerosis plaques is a significant factor in the genesis of gray matter atrophy.Article

THE CONTINUUM OF MULTISYSTEM TDP-43 PROTEINOPATHIES

Geser and colleaguesArticle show in a comprehensive study that amyotrophic lateral sclerosis, frontotemporal lobar degeneration with motor neuron disease, and frontotemporal lobar degeneration with ubiquitinated inclusions are different manifestations of a multiple-system transactivation response DNA-binding protein 43 (TDP-43) proteinopathy linked to similar mechanisms of neurodegeneration.

MEASURING Β-AMYLOID PROTEIN OLIGOMERS IN HUMAN PLASMA AND THE BRAINS OF PATIENTS WITH ALZHEIMER DISEASE

Xia et alArticle report that an oligomeric specific enzyme-linked immunosorbent assay shows a tight link between oligomeric assemblies of the β-amyloid protein (oAβ) and Aβ42 monomer levels in the plasma and brain. This new assay provides the opportunity to study levels of oAβ in plasma in patients with Alzheimer disease to diagnose the presence and amount of an oligomeric form of Aβ that can potentially correlate with cognitive loss.

RAPID PROGRESSIVE NEURODEGENERATIVE DEMENTIAS

Josephs and colleaguesArticle report that in addition to Creutzfeldt-Jakob disease (CJD), other causes of a rapidly progressive neurodegenerative dementia also include frontotemporal lobar degeneration with motor neuron disease, diffuse Lewy body disease, tauopathies, and Alzheimer disease. If the illness duration is more than 12 months, a non-CJD neurodegenerative disease may be a more likely diagnosis than CJD.

CREUTZFELDT-JAKOB DISEASE VARIANTS

Appleby et alArticle report in a detailed and interesting study that classic Creutzfeldt-Jakob disease and the Heidenhain, Oppenheimer-Brownell, cognitive, and affective sporadic variants of Creutzfeldt-Jakob disease differ by age at disease onset, progression, and diagnostic test results.

Place holder to copy figure label and caption

Survival analysis of sporadic Creutzfeldt-Jakob disease (sCJD) variants (log-rank test, χ25 = 25.3, P < .001). CJD indicates Creutzfeldt-Jakob disease.

Graphic Jump Location

MEDITERRANEAN DIET AND MILD COGNITIVE IMPAIRMENT

Scarmeas et alArticle find that adherence to the Mediterranean diet is associated with a trend for reduced risk for developing mild cognitive impairment and with a reduced risk for mild cognitive impairment converting to Alzheimer disease.

AFRICAN ANCESTRY AT HLA MODIFIES MULTIPLE SCLEROSIS PHENOTYPES

Cree and colleaguesArticle show that the role of HLA in multiple sclerosis is not limited to disease susceptibility, but that genes embedded in this locus also influence clinical outcomes.

BENIGN MULTIPLE SCLEROSIS IS CHARACTERIZED BY A LOWER RATE OF BRAIN ATROPHY AS COMPARED WITH EARLY MULTIPLE SCLEROSIS

Gauthier et alArticle report that serial magnetic resonance imaging showed a low 2-year rate of brain atrophy in clinically benign multiple sclerosis, suggesting a less prominent degenerative component in its pathogenesis than in patients with typical early multiple sclerosis. Identification of patients with a low rate of brain atrophy may indicate a benign course.

SPORADIC AND HEREDITARY BRACHIAL PLEXUS NEUROPATHY

Klein et alArticle find that patients with rare sporadic brachial plexus neuropathy (S-BPN) may have the same conserved 17q25 sequence found in many American hereditary BPN kindreds. Patients with BPN with this conserved sequence do not appear to have SEPT9 mutations or alterations of its messenger RNA expression levels in lymphoblast cultures. Patients with BPN with this conserved sequence are predicted to have the most common genetic cause in the Americas by a founder effect mutation.

FMR1 PREMUTATION ALLELES IN WOMEN WITH PARKINSONISM

Cilia and colleaguesArticle show that screening of women with the parkinsonism clinical spectrum is unlikely to be productive in the absence of additional medical or family history suggesting involvement of the FMR1 gene.

GENOMEWIDE ASSOCIATION RESULTS SUGGEST GAB2 AS AN ALZHEIMER DISEASE SUSCEPTIBILITY GENE

Schjeide et alArticle report that GAB2 contains genetic variants that may lead to a modest change in the risk for Alzheimer disease.

Figures

Place holder to copy figure label and caption

Survival analysis of sporadic Creutzfeldt-Jakob disease (sCJD) variants (log-rank test, χ25 = 25.3, P < .001). CJD indicates Creutzfeldt-Jakob disease.

Graphic Jump Location

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

238 Views
0 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs